PATENT CLAIM ANALYSIS

Application Number: 15941063
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["544", "281000"]

Abstract:
Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.

Claim (Index 145):
A method according to  claim 142 , wherein the breast cancer is ER\u03b1-positive breast cancer.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 90.0
- Lexical Diversity: 1.8
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15117982', '12631373', '13773052', '12843494', '13060154']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7835939157146286
- 35 USC 102 Novelty (BERT): 0.564253591228686
- Combined Prediction Score: 0.7616598832660343
- Mean Citation Score: 400.453204
- Max Citation Score: 741.6448
- Similarity Product: 325.2744490806581

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test